Drug Monitoring, Methadone Metabolite, with Confirmation, Urine
Also known as: Prescription Drug Monitoring, Pain Management
Use
Methadone is prescribed to patients for the alleviation of opioid addiction withdrawal symptoms and analgesic purposes. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screening tests are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) confirmation test. Therapeutic urine drug monitoring of methadone and its metabolite EDDP is important for ensuring compliance to treatment strategies, as well as ensuring non‑diversion for illicit purposes strategies. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.
Special Instructions
Not provided.
Limitations
Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine. No single monitoring approach provides adequate information about the pattern or dose of patient drug use.
Methodology
Immunoassay
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
20 mL
Minimum Volume
7 mL
Container
clinical drug test transport vial; random urine collected in a sterile, leak‑proof urine container
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 days |
| Refrigerated | 7 days |
| Frozen | 30 days |
Other tests from different labs that may be relevant